Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

References

• LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med20043502129213915118073
   PubMed Web of Science ®Google Scholar
• PaezJGJannePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience20043041497150015118125
   PubMed Web of Science ®Google Scholar
• PaoWMillerVZakowskiMEGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProc Natl Acad Sci U S A2004101133061331115329413
   PubMed Web of Science ®Google Scholar
• CohenMHWilliamsGASridharaRUnited States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tabletsClin Cancer Res2004101212121814977817
   PubMed Web of Science ®Google Scholar
• JohnsonJRCohenMSridharaRApproval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimenClin Cancer Res2005116414642116166415
   PubMed Web of Science ®Google Scholar
• MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med200936194795719692680
   PubMed Web of Science ®Google Scholar
• FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol2011292866287421670455
   PubMed Web of Science ®Google Scholar
• MitsudomiTMoritaSYatabeYGefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trialLancet Oncol20101112112820022809
   PubMed Web of Science ®Google Scholar
• MaemondoMInoueAKobayashiKGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380238820573926
   PubMed Web of Science ®Google Scholar
• ZhouCWuY-LChenGErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802): a multi-centre, open-label, randomized phase 3 studyLancet Oncol20111273574221783417
   PubMed Web of Science ®Google Scholar
• RosellRGervaisRVergnenegreAErlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trialJ Clin Oncol.201129Suppl Abstr 7503
   Google Scholar
• TohCKGaoFLimWTNever-smokers with lung cancer: epidemiologic evidence of a distinct disease entityJ Clin Oncol2006242245225116710022
   PubMed Web of Science ®Google Scholar
• MorrisSWKirsteinMNValentineMBFusion of a kinase gene ALK, to a nuclear gene, NPM, in non-Hodgkin’s lymphomaScience1994263128112848122112
   PubMed Web of Science ®Google Scholar
• ChiarieRVoenaCAmbrogioCThe anaplastic lymphoma kinase in the pathogenesis of cancerNat Rev Cancer20088112318097461
   PubMed Web of Science ®Google Scholar
• SodaMChoiYLEnomotoMIdentification of the transforming EML4-ALK fusion gene in non-small-cell lung cancerNature200744856156617625570
   PubMed Web of Science ®Google Scholar
• RikovaKGuoAZengQGlobal survey of phosphotyrosine signaling identifies oncogenic kinase in lung cancerCell20071311190120318083107
   PubMed Web of Science ®Google Scholar
• HornLPaoWEML4-ALK: Honing in on a new target in non-small-cell lung cancerJ Clin Oncol2009264232423519667260
   PubMed Web of Science ®Google Scholar
• SasakiTRodigSJChirieacLRThe biology and treatment of EML4-ALK non-small cell lung cancerEur J Cancer2010461773178020418096
   PubMed Web of Science ®Google Scholar
• SodaMTakadaSTakeuchKA mouse model for EML4-ALK positive lung cancerProc Natl Acad Sci U S A2008105198931989719064915
   PubMed Web of Science ®Google Scholar
• ShawATSolomonBTargeting anaplastic lymphoma kinase pathway in lung cancerClin Cancer Res2011172081208621288922
   PubMed Web of Science ®Google Scholar
• CuiJJTran-DubeMShenHStructure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)J Med Chem2011546342636321812414
   PubMed Web of Science ®Google Scholar
• ChristensenJGZouHYArangoMECytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphomaMol Cancer Ther200763314332218089725
   PubMed Web of Science ®Google Scholar
• KwakELCamidgeDRClarkJClinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066J Clin Oncol.20092715 Suppl Abstr 3509
   Web of Science ®Google Scholar
• TanWWilnerKDBangYPharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patientsJ Clin Oncol201028Suppl 15 Abstr 2596
   Web of Science ®Google Scholar
• CostaDBKobayashiSPandyaSSCSF concentration of the anaplastic lymphoma kinase inhibitor crizotinibJ Clin Oncol.201129e443e44521422405
   PubMed Web of Science ®Google Scholar
• KwakELBangY-JCamidgeDRAnaplastic lymphoma kinase inhibition in non-small-cell lung cancerN Engl J Med20103631693170320979469
   PubMed Web of Science ®Google Scholar
• CamidgeDRBangYKwakELProgression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC)J Clin Oncol.201129Suppl Abstr 2501
   Google Scholar
• OuS-HIBazhenovaLCamidgeDRRapid and dramatic radiographic and clinical response to an ALK inhibitor (crizotinib, PF02341066) in an ALK translocation-positive patient with non-small cell lung cancerJ Thorac Oncol201052044204621102269
   PubMed Web of Science ®Google Scholar
• CrinòLKimDRielyGJInitial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005J Clin Oncol201129Suppl Abstr 7514
   PubMedGoogle Scholar
• Xalkori [crizotinib, package insert]New York, NYPfizer Inc2011
   Google Scholar
• NickensDTanWWilnerKPharmacokinetic/pharmacodynamic evaluation of the concentration-QTc relationship of crizotinib (PF-02341066), an anaplastic lymphoma kinase and c-MET/hepatocyte growth factor receptor dual inhibitor administered orally to patients with advanced cancerPoster presented at the 101st annual meeting of the American Association for Cancer ResearchWashington, DCApril 17–21, 2010 Abstr 1673
   Google Scholar
• OuS-HIAzadaMDyJAsymptomatic profound sinus brady-cardia (heart rate <45) in non-small cell lung cancer patients treated with crizotinibJ Thorac Oncol201162135213722088989
   PubMed Web of Science ®Google Scholar
• OuSISalgiaRClarkJWComparison of crizotinib (PF-02341066) pharmacokinetics between Asian and non-Asian patients with advanced malignanciesJ Thorac Oncol20105Suppl 5S382
   Google Scholar
• CamidgeDRKonoSAFlaccoAOptimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatmentClin Cancer Res2010165581559021062932
   PubMed Web of Science ®Google Scholar
• TakeuchiKChoiYLSodaMMultiplex reverse transcription-PCR screening for EML4-ALK fusion transcriptsClin Cancer Res2008146618662418927303
   PubMed Web of Science ®Google Scholar
• Mino-KenudsonMChirieacLRLawKA novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistryClin Cancer Res2010161561157120179225
   PubMed Web of Science ®Google Scholar
• YiESBolandJMMaleszewskiJJCorrelation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma. IHC score algorithm for FISHJ Thorac Oncol2011645946521278610
   PubMed Web of Science ®Google Scholar
• PaikJHChoeGKimHScreening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer. Correlation with fluorescence in situ hybridizationJ Thorac Oncol2011646647221258247
   PubMed Web of Science ®Google Scholar
• CataldoKAJalalSMLawMEDetection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissueAm J Surg Pathol1999231386139210555007
   PubMed Web of Science ®Google Scholar
• ButrynskiJED’AdamoDRHornickJLCrizotinib in ALK-rearranged inflammatory myofibroblastic tumorN Engl J Med20103631727173320979472
   PubMed Web of Science ®Google Scholar
• Gambacorti-PasseriniCMessaCCrizotinib in anaplastic large-cell lymphomaN Engl J Med201136477577621345110
   PubMed Web of Science ®Google Scholar
• OuS-HIKwakELSiwak-TappCActivity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplificationJ Thorac Oncol2011694294621623265
   PubMed Web of Science ®Google Scholar
• LennerzJKEwakELMichaelMIdentification of small and lethal subgroup of esophagogastric adenocarcinoma with evidence of response to crizotinib by MET amplificationJ Clin Oncol.201129Suppl Abstr 4130
   Google Scholar
• ChiASKwakELClarkJWClinical improvement and rapid radiographic regression induced by a MET inhibitor in a patient with MET-amplified glioblastomaJ Clin Oncol.201129Suppl Abstr 2072
   Google Scholar
• RobinsonDRWuY-MLinS-FThe protein tyrosine receptor kinase family of the human genomeOncogene2000195548555711114734
   PubMed Web of Science ®Google Scholar
• BergethonKShawATOuS-HIROS1 rearrangements define a unique class of lung cancersJ Clin Oncol2012 In press
   Web of Science ®Google Scholar
• PaoWChmieleckiJRational, biologically based treatment of EGFR-mutant non-small-cell lung cancerNat Rev Cancer20101076077420966921
   PubMed Web of Science ®Google Scholar
• ChoiYLSodaMYamashitaYEML4-ALK mutations in lung cancer that confer resistance to ALK inhibitorsN Engl J Med20103631734173920979473
   PubMed Web of Science ®Google Scholar
• KatayamaRKhanTMBenesCTherapeutic strategies to over-come crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProc Natl Acad Sci U S A20111087535754021502504
   PubMed Web of Science ®Google Scholar
• SasakiTOkudaKZhangWThe neuroblastoma associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK translocated cancersCancer Res201070100381004321030459
   PubMed Web of Science ®Google Scholar
• SakamotoHTsukaguchiTHiroshimaSCH542802, a selective ALK inhibitor capable of blocking the resistance gatekeeper mutantCancer Cell20111967969021575866
   PubMed Web of Science ®Google Scholar
• SasakiTKoivunenJOginoAA novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitorsCancer Res2011716051606021791641
   PubMed Web of Science ®Google Scholar
• HeuckmannJMHolzelMSosMLALK mutations conferring differential resistance to structurally diverse ALK inhibitorsClin Cancer Res September 262011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• TrapelJMollapourMGiacconeGTargeting the dynamic HSP90 complex in cancerNat Rev Cancer20101053754920651736
   PubMed Web of Science ®Google Scholar
• NormantEPaezGWestKAThe Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC modelsOncogene2011302581258621258415
   PubMed Web of Science ®Google Scholar
• SequistLVGettingerSNeilNNActivity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerJ Clin Oncol2010284953496020940188
   PubMed Web of Science ®Google Scholar
• WongKKoczywasMGoldmanJWAn open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC)J Clin Oncol201129Suppl Abstr 7500
   Google Scholar
• CohenMHWilliamsGASridharaRUnited States Food and Drug Administration drug approval summary: gefitinib (ZD1839; Iressa) tabletsClin Cancer Res2004101212121814977817
   PubMed Web of Science ®Google Scholar
• ThatcherNChangAParikhPGefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)Lancet20053661527153716257339
   PubMed Web of Science ®Google Scholar
• ChangAParikhPThongprasertSGefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL studyJ Thorac Oncol2006184785517409969
   PubMed Web of Science ®Google Scholar
• CamidgeDRKonoSALuXAnaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexedJ Thorac Oncol2011677478021336183
   PubMed Web of Science ®Google Scholar
• LeeJ-OKimTMLeeS-HAnaplastic lymphoma kinase translocation. A predictive biomarker of pemetrexed in patients with non-small cell lung cancerJ Thorac Oncol201161474148021642865
   PubMed Web of Science ®Google Scholar
• Paz-AresLGDe MarinisFDediuMPARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)J Clin Oncol201129Suppl Abstr CRA7510
   Google Scholar
• PaikPKArcilaMEFaraMClinical characteristics of patients with lung adenocarcinomas harboring BRAF mutationsJ Clin Oncol2011292046205021483012
   PubMed Web of Science ®Google Scholar
• MarchettiAFelicioniLMalatestaSClinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutationsJ Clin Oncol2011293574257921825258
   PubMed Web of Science ®Google Scholar